Hexagon Bio, Inc

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Palo Alto, California, focused on developing innovative treatments for prevalent retinal diseases. Founded by experienced leaders in ophthalmology, the company aims to address significant unmet needs by creating therapies that ease the burden on patients and caregivers while improving treatment outcomes. The company's lead product, TH103, is a fully humanized recombinant fusion protein designed for intravitreal delivery, demonstrating potential as a best-in-class anti-VEGF agent. With an experienced management team and support from veteran investors, Kalaris is currently evaluating TH103 in a Phase 1 clinical trial for neovascular age-related macular degeneration, with plans to expand its application to other neovascular and exudative retinal diseases. Generated from the website

AN2 Therapeutics, Inc., based in Atherton, CA, is dedicated to developing novel therapies through its innovative boron chemistry platform. The company's experienced leaders are committed to enhancing global human health by delivering first-in-class drug discovery approaches targeting infectious diseases and oncology. With a promising pipeline of boron-based compounds, AN2 Therapeutics aims to create best-in-class therapeutics, including their investigational drugs for conditions such as Chagas disease and melioidosis. Their mission reflects a passion for scientific advancement and an unwavering focus on improving patient outcomes. Generated from the website

AstraZeneca is a global biopharmaceutical company dedicated to transforming the future of healthcare through innovative science and technology. The company focuses on precision medicine and transformative science, emphasizing the importance of data science and clinical innovation to deliver medical breakthroughs for millions of people worldwide. With a diverse pipeline encompassing oncology, biopharmaceuticals, cardiovascular health, and more, AstraZeneca aims to champion sustainability and inclusivity within its operational framework. The organization is committed to advancing health systems resilience and improving community health equity through partnerships and responsible governance. Generated from the website